Glaxosmithkline Dividends - GSK

Glaxosmithkline Dividends - GSK

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Glaxosmithkline Plc GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change Price Change % Stock Price Last Trade
-12.00 -0.84% 1,423.40 16:35:13
Open Price Low Price High Price Close Price Previous Close
1,435.40 1,420.20 1,438.80 1,423.40 1,435.40
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Glaxosmithkline GSK Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
05/02/2020FinalGBX2331/12/201831/12/201920/02/202021/02/202009/04/202080
30/10/20191GBX1931/12/201831/12/201914/11/201915/11/201909/01/20200
24/07/20191GBX1931/12/201831/12/201908/08/201909/08/201910/10/20190
01/05/20191GBX1931/12/201831/12/201916/05/201917/05/201911/07/20190
06/02/2019FinalGBX2331/12/201731/12/201821/02/201922/02/201911/04/201980
31/10/20181GBX1931/12/201731/12/201815/11/201816/11/201810/01/20190
25/07/20181GBX1931/12/201731/12/201809/08/201810/08/201811/10/20180
25/04/20181GBX1931/12/201731/12/201810/05/201811/05/201812/07/20180
07/02/2018FinalGBX2331/12/201631/12/201722/02/201823/02/201812/04/201880
25/10/20171GBX1931/12/201631/12/201709/11/201710/11/201711/01/20180
26/07/20171GBX1931/12/201631/12/201710/08/201711/08/201712/10/20170
26/04/20171GBX1931/12/201631/12/201711/05/201712/05/201713/07/20170
08/02/2017FinalGBX2331/12/201531/12/201623/02/201724/02/201713/04/201780
26/10/20161GBX1931/12/201531/12/201603/11/201604/11/201612/01/20170
27/07/20161GBX1931/12/201531/12/201611/08/201612/08/201613/10/20160
27/04/20161GBX1931/12/201531/12/201612/05/201613/05/201614/07/20160
03/02/2016SpecialGBX2031/12/201431/12/201518/02/201619/02/201614/04/20160
03/02/2016FinalGBX2331/12/201431/12/201518/02/201619/02/201614/04/2016100
19/10/20151GBX1931/12/201431/12/201512/11/201513/11/201514/01/20160
29/07/20151GBX1931/12/201431/12/201513/08/201514/08/201501/10/20150
06/05/20151GBX1931/12/201431/12/201514/05/201515/05/201509/07/20150
04/02/2015FinalGBX2331/12/201331/12/201419/02/201520/02/201509/04/201580
22/10/20141GBX1931/12/201331/12/201406/11/201407/11/201408/01/20150
24/07/20141GBX1931/12/201331/12/201406/08/201408/08/201402/10/20140
30/04/20141GBX1931/12/201331/12/201414/05/201416/05/201410/07/20140
05/02/2014FinalGBX2331/12/201231/12/201319/02/201421/02/201410/04/201478
23/10/20131GBX1931/12/201231/12/201313/11/201315/11/201309/01/20140
24/07/20131GBX1831/12/201231/12/201307/08/201309/08/201303/10/20130
24/04/20131GBX1831/12/201231/12/201308/05/201310/05/201311/07/20130
06/02/2013FinalGBX2231/12/201131/12/201220/02/201322/02/201311/04/201374
31/10/20121GBX1831/12/201131/12/201214/11/201216/11/201203/01/20130
25/07/20121GBX1731/12/201131/12/201208/08/201210/08/201204/10/20120
25/04/20121GBX1731/12/201131/12/201209/05/201211/05/201205/07/20120
07/02/2012SpecialGBX531/12/201031/12/201115/02/201217/02/201212/04/20120
07/02/2012FinalGBX2131/12/201031/12/201115/02/201217/02/201212/04/201275
26/10/2011InterimGBX1731/12/201031/12/201102/11/201104/11/201105/01/20120
26/07/2011InterimGBX1631/12/201031/12/201103/08/201105/08/201106/10/20110
27/04/2011InterimGBX1631/12/201031/12/201104/05/201106/05/201107/07/20110
03/02/2011FinalGBX1931/12/200931/12/201009/02/201111/02/201107/04/201165
21/10/2010InterimGBX1631/12/200931/12/201027/10/201029/10/201006/01/20110
21/07/2010InterimGBX1531/12/200931/12/201028/07/201030/07/201007/10/20100
28/04/2010InterimGBX1531/12/200931/12/201005/05/201007/05/201008/07/20100
04/02/2010FinalGBX1831/12/200831/12/200910/02/201012/02/201008/04/201061
29/10/20091GBX1531/12/200831/12/200904/11/200906/09/200907/01/20100
30/07/20091GBX1431/12/200831/12/200931/07/200931/07/200908/10/200928
22/04/20091GBX1431/12/200831/12/200929/04/200901/05/200909/07/20090
05/02/2009FinalGBX1731/12/200731/12/200811/02/200913/02/200909/04/200957
22/10/20081GBX1431/12/200731/12/200829/10/200831/10/200809/01/20080
07/02/2008FinalGBX1331/12/200631/12/200713/02/200815/02/200810/04/200853
25/07/20071GBX1231/12/200631/12/200701/08/200703/08/200711/10/20070
24/04/20071GBX1231/12/200631/12/200702/05/200704/05/200712/07/20070
08/02/20071GBX1431/12/200531/12/200614/02/200616/02/200612/04/20070
08/02/2007FinalGBX031/12/200531/12/200601/01/197001/01/197001/01/197048
26/10/20061GBX1231/12/200531/12/200601/11/200603/11/200604/01/20070
26/07/20061GBX1131/12/200531/12/200602/08/200604/08/200605/10/20060
27/04/20061GBX1131/12/200531/12/200610/05/200612/05/200606/07/20060
08/02/2006FinalGBX1431/12/200431/12/200515/02/200617/02/200606/04/200644
27/10/20051GBX1031/12/200431/12/200502/11/200504/11/200505/01/20060
29/07/20051GBX1031/12/200431/12/200503/08/200505/08/200506/10/20050
28/04/20051GBX1031/12/200431/12/200511/05/200513/05/200507/07/20050
10/02/2005FinalGBX1231/12/200331/12/200416/02/200518/02/200507/04/200542
28/10/20041GBX1031/12/200331/12/200403/11/200405/11/200406/01/20050
27/07/20041GBX1031/12/200331/12/200412/05/200414/05/200401/07/20040
27/07/20041GBX1031/12/200331/12/200404/08/200406/08/200430/09/20040
12/02/2004FinalGBX1431/12/200231/12/200318/02/200420/02/200415/04/200441
11/02/20041GBX931/12/200231/12/200329/10/200331/10/200306/01/20040
23/07/20031GBX931/12/200231/12/200330/07/200301/08/200302/10/20030
30/04/20031GBX931/12/200231/12/200307/05/200309/05/200303/07/20030
12/02/2003FinalGBX1331/12/200131/12/200219/02/200321/02/200317/04/200340
23/10/20021GBX930/03/200230/09/200230/10/200201/11/200203/01/20030
24/07/20021GBX930/12/200130/06/200231/07/200202/08/200203/10/20020
25/04/20021GBX901/10/200131/03/200201/05/200203/05/200204/07/20020
14/02/2002FinalGBX1231/12/200031/12/200120/02/200222/02/200218/04/200239
23/10/20011GBX930/09/200030/09/200131/10/200102/11/200103/01/20020
24/07/20011GBX930/06/200030/06/200101/08/200103/08/200104/10/20010
24/04/20011GBX931/03/200031/03/200102/05/200104/05/200105/07/20010
13/12/2000FinalGBX2331/12/199931/12/200018/12/200022/12/200017/04/200138
27/07/2000InterimGBX1530/12/199930/06/200007/08/200011/08/200016/10/20000
16/02/2000FinalGBX2231/12/199831/12/199928/02/200003/03/200025/05/200037
29/07/1999InterimGBX1530/12/199830/06/199909/08/199913/08/199901/10/19990
18/02/1999FinalGBX2131/12/199731/12/199801/03/199905/03/199920/05/199936

Top Dividend Posts

DateSubject
17/6/2021
07:14
grahamite2: New GSK plans are ‘underappreciated’, says Liberum A part-initial public offering (IPO) of the consumer division of GlaxoSmithKline (GSK) looks increasingly likely, says broker Liberum. Analyst Alistair Campbell reiterated his ‘buy’ recommendation and target price of £17 on the pharmaceutical giant, which closed up 1.3%, or 19p, at £14.36 on Wednesday. The group will next week host an event called ‘New GSK’ that will set out the growth aspirations for the business after the consumer division has been hived off. ‘We forecasts sales growth of 6% per annum and earnings growth of 10% per annum for 2021-26, both a touch ahead of consensus,’ said Campbell. ‘GSK will also clarify the consumer separation plan, with debate as to whether this will be a spin-off or IPO. A part-IPO looks increasingly likely, particularly if GSK wants to invest in the pipeline.’ Campbell said this structure may add ‘further uncertainty to the process’, but over the long-term the potential for ‘New GSK is underappreciated’. Https://citywire.co.uk/funds-insider/news/expert-view-glaxo-pets-at-home-wickes-oxford-instruments-and-scs/a1519997?re=86118&ea=254058&utm_source=BulkEmail_FundsInsider+DawnChorus&utm_medium=BulkEmail_FundsInsider+DawnChorus&;utm_campaign=BulkEmail_FundsInsider+DawnChorus#i=2
14/6/2021
17:22
xxxxxy: Drug-making giant GlaxoSmithKline today announced a $2 billion tie-up with a US-based biotech to strengthen its lacklustre drugs pipeline in advance of a long-awaited corporate split.The group said the deal with Boston-based iTeos Therapeutics will place its pharma and vaccines arm at the forefront of research into next-generation treatment for a range of cancers.Under the deal, worth $625 million upfront with another $1.45 billion in milestone payments, the two companies will co-develop and market a monoclonal antibody which targets part of the immune system - known as checkpoint CD226 - to help the body fight tumours.It is the latest of more than 20 buy-ups and partnerships announced in the past 12 months as GSK shores up cancer and vaccine research, before cleaving its pharma and consumer divisions into two separate companies.The announcement follows a bruising weekend of briefings which saw insiders attempt to pin blame for GSK's "flat-footed" Covid-19 vaccine response - compared to that of FTSE 100 rival AstraZeneca - onto CEO Dame Emma Walmsley.Some shareholders say it has solidified doubts over whether Walmsley, who lacks a strong science background, should lead the new pharma company as planned.But her supporters respond that the £70 billion supertanker of a company she inherited in 2017 will take at least a decade to turn around, a process that is now apace after four years at the helm.Either way, there is pressure to impress investors - including famously aggressive US hedge fund Elliott Management which has built up a multibillion-pound stake - at a capital markets day on June 23, when details of next year's split will be formally unveiled.It will be its biggest restructuring since Glaxo Wellcome merged with SmithKline Beecham in 2000 to create the company in its present form.And with shares down around 15% over Walmsley's four-year tenure, much is riding on deals such as the one announced today.GSK said the tie-up will make it the only pharma company with access to antibodies that block all three known cancer checkpoints at the key CD226 axis.It already partners with genetic testing company 23andMe and Surface Oncology on the two others, CD96 and PVRIG.The TIGIT inhibitor being developed by iTeos - which went public on the Nasdaq last summer with a $200million valuation - completes the set.Researchers will deploy different combinations of treatments against the three targets, each of which can turn the immune system off and prevent it from fighting cancer, to evaluate their effectiveness against multiple cancers.GSK chief scientific officer Dr Hal Barron said immuno-oncology - the science of harnessing a patient's immune system to fight tumours - had transformed cancer care but less than 30 percent of patients respond to treatment with existing checkpoint inhibitors.He said: "Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer."We are excited to collaborate with the team at iTeos and together we can play a leading role in the next generation of immuno-oncology therapies."The group, which employs 94,000, has had relatively few blockbuster launches of late and relies on its existing portfolio of products, of which 14 will lose their patents in the next decade.But latest analysis suggests there are more than 20 assets in its late-stage pipeline which could hit the market by 2026.Michel Detheux, president and CEO, iTeos said: "Through this transformative collaboration, iTeos now has access to GSK's best-in-class resources which will provide us with a significant advantage in a highly competitive, global market."Shares in iTeos shot up 50% in pre-market trading on the Nasdaq. Having risen and fallen sharply since the launch at $19 last July jumped 48.2% to $29.69c.GSK's share price continued their upward trajectory this month, up 7p or 0.5%, to 1410.4p..... Yahoo Finance
09/6/2021
21:35
eurofox: The problem here is the mentality of some traders and amateur investors, who have completely unrealistic expectations for dividend yield in today's low interest environment. A 50p dividend would at today's share price still be a 4% yield, anything else is greedy and unsustainable.
03/6/2021
15:05
sajad37: Print Edition Read pdf version Subscribe now HOME     JobsCorporate PrContact UsAbout ArabnewsAdvertisePrivacy & Terms Of Service © 2020 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement. Saudi Chemical agrees $27m GlaxoSmithKline manufacturing deal ARAB NEWS 03 June 2021     GSK House, the headquarters of the pharmaceutical giant in the UK. (Supplied) Short Url hxxps://arab.news/ggef4 Five year deal will bring pharma manufacturing to the KingdomPartnership could help spur jobs localization RIYADH: Saudi Chemical Company Holding (SCCH) has struck a deal with GlaxoSmithKline to make pharmaceutical products in the Kingdom. SCCH unit AJA Pharmaceutical Industries will team up with GlaxoSmithKline Consumer Healthcare Saudi in a five-year production deal worth SR100 million ($27 million), the company said in a Saudi stock exchange filing on Thursday. The new partnership would help create more jobs for Saudis in the Kingdom’s pharmaceuticals sector said SCCH CEO Thamer Al-Muhid, “Our mission is to be the partner of choice,” he said. Saudi Arabia aims to diversify its economy away from oil by adding more high value jobs at home and replacing imports with domestic manufacturing in key sectors such as pharmaceuticals.     Topics: GSK SAUDI ARABIA UK PHARMACEUTICALS Related Sanofi, GSK launch final phase of COVID vaccine trials GSK to produce 1 billion doses of coronavirus vaccine booster in 2021 Opinion MORE IN OPINION Latest Updates Columnist EMAIL ALERTSStay on top of the issues that matter to you the most.   SAUDI ARABIAMIDDLE EASTWORLDBUSINESSSPORT LIFESTYLEOPINIONMEDIAROAD TO 2030JOBS     Corporate PrContact UsAdvertisePrivacy & Terms Of Service © 2019 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement.
27/5/2021
10:47
xxxxxy: GlaxoSmithKline (GSK.L) has launched a new trial for a COVID-19 vaccine, while an existing antibody treatment has received an emergency use authorisation from the US.The pharmaceutical giant, which has been looking to bring a new coronavirus vaccine to the market by the end of the year, announced on Thursday that it has initiated a global phase three clinical efficacy study.The vaccine could be approved in the fourth quarter of 2021 pending positive outcomes and regulatory reviews, the company said. Manufacturing will begin in the coming week to enable rapid access to the vaccine should it be approved.The company, which is lagging behind its rivals in the fight against coronavirus, has partnered with French firm Sanofi.The new trial follows the interim phase two results which showed that their vaccine candidate achieved high rates of neutralising antibody responses in all adult age groups, with 95% to 100% seroconversion rates.After a single injection, high neutralising antibody levels were also generated in participants with evidence of prior infection, which suggests strong potential for development as a booster vaccine, GSK said.?GSK shares were flat on Thursday. Chart: Yahoo FinanceMore"We believe further solutions for COVID-19 are very much needed to help reach people around the world, especially as the pandemic evolves and variants continue to emerge," said Roger Connor, president of GSK vaccines."Adjusting our technology and study designs reflects this need and will further build the potential of this adjuvanted protein-based vaccine. We are grateful to the volunteers who will take part in the trials and hope the results will add to the encouraging data we've seen so far so we can make the vaccine available as quickly as possible."The GSK vaccine was originally expected to receive regulatory approval in the first half of this year, however, it was delayed in December as it failed to produce a strong immune response in older people.The UK had pre-ordered around 60 million doses of the GSK-Sanofi vaccine as of December.Read more: COVID vaccine boosts UK investor confidence but Brexit fears still lingerThe news came as an antibody treatment called sotrovimab received an emergency green light from the US Food and Drug Administration (FDA) to treat mild-to-moderate COVID-19 in people 12 years of age and older.GSK revealed that treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalisation or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial.It will be available for patients diagnosed with COVID-19 in the US in the coming weeks, while discussions with global regulators in additional countries continue. The antibody drug is not authorised for patients who require oxygen therapy.Read more: Japan approves AstraZeneca COVID vaccine ahead of Tokyo OlympicsThe news comes as Emma Walmsley, GSK's chief executive, has been put under pressure after activist investor Elliott Management took a multibillion-pound stake in the company in April.The US hedge fund is known for having waged campaigns for change at a number of high-profile firms, including mining group BHP (BHP.L), and Premier Inn owner Whitbread (WTB.L).According to the Times on Thursday, Elliott Management will not push for a sale of GSK's vaccines and pharmaceuticals business. It is also understood that it is not planning to push for cuts to the company's £5bn ($7bn) research and development budget, and will be supportive of GSK remaining in the UK..... Yahoo Finance
22/5/2021
19:13
xxxxxy: HL COMMENT (28 APRIL 2021)GlaxoSmithKline (GSK) reported first quarter turnover of £7.4bn, down 15% at constant exchange rates. That reflects declines across all three divisions, as consumers and healthcare groups ran down stockpiles built up earlier in the year and vaccine sales slid as governments prioritised Covid vaccinations.Despite a decline in year-on-year operating costs, underlying operating profit fell 23% to £1.9bn.The group announced a quarterly dividend of 19p per share, and continues to expect to hit the full year target of 80p per share.GSK shares were broadly unmoved following the announcement.Our viewGSK's struggling against some formidable headwinds - and, honestly, first quarter results are not showing much of an improvement.You might have thought a global healthcare crisis would be good for pharma groups. However, GSK's own vaccine candidates are still in trial phases, and as a result the effect of the pandemic has been all negative. Non-coronavirus vaccines - a key money spinner for GSK - have been delayed and demand for other pharmaceutical products has been hit as lockdowns kept patients away from doctors' surgeries.Meanwhile the group is dealing with the fallout of patents on certain key drugs coming to an end. That's an inevitable part of being in pharmaceuticals - but the collapse in Advair and Ventolin sales is offsetting much of the progress in newer drugs. That headwind has further to run.It doesn't help that the Consumer Healthcare business is showing some very mixed results - with good numbers for vitamins and minerals (largely acquired from Pfizer) offset by lacklustre performances elsewhere.It's not a perfect backdrop for the transformational plans CEO Emma Walmsley has for the group. By 2022 it will have split into two companies, one taking the BioPharama assets and the other the Consumer Healthcare brands. In general though, the move makes sense. Two businesses with a sharper focus should be more efficient than one conglomerate, and it will help reduce the confusion around exactly what GSK is offering investors. But it also means investors are buying into what will one day be two radically different businesses.The consumer division should be a 'steady eddie' with hopefully more predictable returns. As one of the world's largest over-the-counter medicines businesses, it should be able to achieve significant efficiencies, ultimately giving the group attractive margins.However, performance from these brands leaves something to be desired. We also expect the new company to get saddled with a disproportionally large share of the group's debt when it goes its own way, and that could hamper shareholder returns.For the pharma group, losing the steady cash flows of the consumer business means there's more pressure on the labs to come up with new drugs before old ones fall off. Increased focus on vaccine preparedness going forwards will help, since vaccines tend to offer longer term sources of revenue. But it's vital its research teams deliver the next generation of blockbusters.The pipeline has delivered some reasonable results thus far - although it's been unable to offset the loss of legacy sales more recently. HIV, Oncology and Vaccines are all delivering new drugs with 59 medicines and vaccines in development. But the problem any pure-play pharmaceuticals business faces is that even the most promising drugs can fall at the final hurdle.It's also worth noting that management expect the separate businesses to pay a lower dividend overall than GSK has been able to support to date. The size of that cut is as yet unclear.While we see some real bright spots in GSK, there's a lot of murky corners too. A 5.6% prospective dividend yield will inevitably attract some investors, but remember that's only temporary and not guaranteed. In its present form GSK struggles to present a clear picture of what it offers investors -hopefully its successor companies are a little more streamlined..... hl.co.uk
20/5/2021
18:49
bull19: All other things being equal, share price will always drop by the dividend amount on ex dividend. The reason it doesn't actaully result in an exact decrease of that amount is because there are always other factors affecting share price. The fact that GSK notionally increased by 12.2p has nothing to do with the dividend. The FTSE100 increased 1% today and the 12.2p "increase" in GSK is in line with that.
20/5/2021
16:20
tradermichael: GlaxoSmithKline has sold its entire stake in Innoviva back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on Thursday, as it simplifies operations ahead of a split into two businesses. The London-listed company said it sold roughly 32 million shares in the Nasdaq-listed Innoviva for $12.25 per share, a marginal discount to the stock's closing price of $12.29 on Wednesday. GSK will give details in June on its plan to separate next year into an over-the-counter products business and another for prescription drugs and vaccines. Preparations have hurt earnings, but the company hopes the streamlining will pay off in the long term. Shares of GSK were 0.3% lower at 1,361.3 pence by 1427 GMT, while Innoviva gained 5.1% to about $13. An existing collaboration between the companies on respiratory treatments is not affected by the share sale, GSK said, adding the disposal frees up capital to help make more investments in line with its strategic priorities. Under the respiratory deal, GSK pays royalties to Innoviva on lung drugs Trelegy Ellipta, Relvar/Breo Ellipta and Anoro Ellipta that the companies co-developed.
18/5/2021
16:39
zeppo: Selling the excellent brands in the consumer side started years ago. How can we believe that drugs will make up for this loss of income stream?. How many years will it be before they restore a comparable dividend? '09 September 2013: GSK reaches agreement to divest Lucozade and Ribena for £1.35 billion GSK today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd. Issued: London UK – LSE Announcement GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd (SBF), the Japanese consumer goods company, for £1.35 billion in cash. It is expected that the transaction will be completed by the end of the year, subject to regulatory approvals.' I bought this as an income stock. The divi. has been supported by cash coming in from the consumer division.. The future of GSK as an income stock looks dire. May cut my losses on this. I go for income and growth but have some pure growth stocks in the Hydrogen economy.
17/5/2021
10:32
xxxxxy: GlaxoSmithKline (GSK.L) and Sanofi (SNY) reported strong results in COVID-19 vaccine trials on Monday morning, saying the jab had "triggered strong neutralising antibody responses in all adult age groups."In an update it said it had found a high immune response after a single dose in patients with prior infection, showing strong booster potential."Overall, the vaccine candidate elicited strong neutralising antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old)," it said.Phase 3 trials are expected to start in the coming weeks. The phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants.GSK is a FTSE 100 (^FTSE) drugs giant worth about £69bn ($97bn) and employing 94,000 people. Despite its size, it has been something of a laggard in the race to produce a coronavirus vaccine, with several other candidates moving to mass-production and worldwide rollout first, including Pfizer (PFE), the Oxford-AstraZeneca (AZN.L) effort and Moderna (MRNA). GSK stock fell around 0.4% in early trade in London on Monday, in line with the rest of the FTSE 100 index. Read more: Ryanair predicts 'strong recovery in air travel' as it suffers €815m loss"The UK continues to see a very smooth and successful rollout of vaccines, but other countries are still playing catch-up or are experiencing supply shortages," said Russ Mould, investment director at AJ Bell. "That's why it could be better late than never for GlaxoSmithKline which has reported encouraging phase 2 results from its joint vaccine candidate with Sanofi."The more vaccines the better, as that would in theory increase the chance for countries around the world to have a fighting chance of tackling COVID and start living lives normally again," Mould continues, noting that the next stage trials could still put a spanner in the works. GSK recently experienced top-level anxiety in its ranks, with 20 shareholders backing the company amid concerns US activist hedge fund Elliott Management was preparing for a shakeup. Institutional shareholders contacted Sir Jonathan Symonds, GSK's chairman to back up the board's current strategy. The rumblings from Elliott Management came amid apparent discontent from other large shareholders. ... Yahoo Finance
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 19:20:18